Key points
- Loss of appetite was reported by 33% of adults on Adderall XR vs 3% on placebo, and weight loss by 10% vs 0%, in the adult trial in its FDA label.
- In Vyvanse's 4-week adult trial, mean weight loss ranged from 2.8 to 4.3 pounds across dose groups, while the placebo group gained 0.5 pounds on average.
- Decreased appetite was reported by 16% of adults on Strattera (vs 3%) and 10% on Qelbree (vs 3%).
- The Vyvanse label says it is not indicated or recommended for weight loss and notes serious cardiovascular events with other stimulant-type drugs used for weight loss.
- NICE guideline NG87 recommends measuring weight every 6 months in adults taking ADHD medication.
Many adults notice they are less hungry at lunch after starting an ADHD stimulant. For some that is a minor change; for others it means skipped meals, low energy by evening and weight loss they did not want. This page sets out what FDA labels (checked on DailyMed on October 19, 2026) and guidelines say about appetite and weight. It gives no doses and is not advice to start, stop or change any medication.
How common appetite loss is in adult trials
The numbers below come from each label's own placebo-controlled adult trials. The Adderall XR label cautions that rates from one drug's trials cannot be directly compared with another's, so treat each row on its own.
| Medication | Class | Appetite and weight findings in adult trials (drug vs placebo) |
|---|---|---|
| Adderall XR | Stimulant (amphetamine) | Loss of appetite 33% vs 3%; weight loss 10% vs 0%; dry mouth 35% vs 5% |
| Vyvanse | Stimulant (amphetamine prodrug) | Decreased appetite 27% vs 2%; anorexia (marked loss of appetite) 5% vs 0%; decreased weight 3% vs 0%; mean loss of 2.8 to 4.3 pounds at 4 weeks across dose groups vs a 0.5-pound gain on placebo |
| Concerta | Stimulant (methylphenidate) | Decreased appetite 25% vs 7%; decreased weight 7% vs 3%; nausea 13% vs 3% |
| Strattera | Nonstimulant (atomoxetine) | Decreased appetite 16% vs 3%; weight decreased 2% vs 1%; nausea 26% vs 6% |
| Qelbree | Nonstimulant (viloxazine) | Decreased appetite 10% vs 3%; nausea 12% vs 3% |
A 2019 network meta-analysis of 10 adult trials (Chierrito de Oliveira and colleagues, Journal of Attention Disorders) found a statistically significant difference in decreased appetite between placebo and both atomoxetine and extended-release mixed amphetamine salts. Nausea, which is more common with the nonstimulants, can also cut how much a person eats.
Nausea and stomach upset
Appetite is not only about hunger. Stomach side effects can make eating unappealing. In the Strattera adult studies, nausea was reported by 26% of people on the drug vs 6% on placebo, abdominal pain by 7% vs 4%, and constipation by 8% vs 3%. In the Qelbree adult trial, nausea was 12% vs 3% and vomiting 4% vs 1%. Among stimulants, the Concerta adult trials reported nausea in 13% vs 3%, and Adderall XR in 8% vs 3%. Persistent nausea that keeps you from eating is worth raising with the prescriber.
A different picture in binge eating disorder trials
The Vyvanse label also reports 12-week trials in adults with binge eating disorder. There, decreased appetite was reported by 8% of people on Vyvanse vs 2% on placebo, and decreased weight by 4% vs 0%, while dry mouth (36% vs 7%) and insomnia (20% vs 8%) were more common. These trials enrolled a different population with a different goal, so their numbers do not transfer to ADHD treatment, but they show that appetite effects vary by who is taking the drug.
What the label trials do and do not tell you
Most adult trials in these labels lasted four weeks to a few months. They show that appetite loss and early weight loss are common. They do not say how a given adult's weight will change over years of treatment, and the labels' long-term growth data come from children, not adults. That gap is one reason guidelines ask for regular weight checks rather than a one-time warning.
ADHD medications are not weight-loss drugs
Vyvanse is FDA-approved for two conditions: ADHD (adults and children 6 and older) and moderate to severe binge eating disorder in adults. Its label still states that it "is not indicated or recommended for weight loss," that "use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events," and that its safety and effectiveness for treating obesity have not been established. The binge eating disorder approval is for reducing binge-eating days, not for weight loss.
Every prescription stimulant also carries a boxed warning about misuse, abuse and addiction, which the FDA strengthened in 2023. Taking more than prescribed to suppress appetite is a form of misuse. See misuse and addiction risk and Vyvanse for adults.
Eating disorders and ADHD medication
A current or past eating disorder is important history to share before any ADHD medication is chosen. One clear label example: bupropion (Wellbutrin XL), sometimes used off-label for ADHD, is contraindicated in people with a current or prior diagnosis of bulimia or anorexia nervosa, because of seizure risk. More on that medication is on the bupropion page. With stimulants, appetite loss in someone who already restricts food is a reason for closer follow-up, so the prescriber needs to know.
What monitoring looks like
The UK's NICE guideline NG87 is one of the few guidelines that gives adult-specific numbers. It recommends:
- Measuring weight every 6 months in adults taking ADHD medication.
- Considering BMI monitoring in adults whose weight changed as a result of treatment, and a change of medication if weight change persists.
- Checking heart rate and blood pressure before and after each dose change and every 6 months.
The New York and New Jersey rules on prescriptions for controlled stimulants, which shape how often visits happen, are summarized in ADHD medication rules in New York and ADHD medication rules in New Jersey.
Strategies guidelines list for unwanted weight loss
When weight loss is a clinical concern, NICE NG87 lists these strategies. They are options for you and your prescriber to weigh together, not steps to take alone:
- Taking medication with or after food rather than before meals.
- Adding meals or snacks early in the morning or late in the evening, when stimulant effects have worn off.
- Getting dietary advice.
- Eating high-calorie foods of good nutritional value.
- A planned break from treatment.
- Changing medication.
The last two are medication decisions and belong with the prescriber. Labels also differ on food: the Adderall XR Medication Guide, for example, says it can be taken with or without food. Ask before changing how you take any product.
When to contact the prescriber
- You are losing weight you did not intend to lose, or regularly skipping meals.
- Nausea, stomach pain or low appetite is making it hard to eat enough.
- You have, or have had, an eating disorder, or you notice urges to restrict or binge.
- You feel dizzy, weak or unusually tired in the afternoon or evening.
Seek emergency care for chest pain, shortness of breath or fainting; stimulant Medication Guides say to call the prescriber or go to the nearest emergency room right away for those symptoms. The full list of urgent symptoms is in ADHD medication side effects in adults.
Questions to ask
- How common is appetite loss with the medication you are suggesting, and does it usually change over time for your patients?
- How and when will my weight be checked, given that follow-up is by video?
- What should I do if I am not hungry at lunch on workdays?
- Does my history (eating disorder, low body weight, diabetes) change which medication fits?
A home scale and a simple log make video follow-up work. Dr. Shershow's evaluation covers medical history and medications, and medication management continues by secure video; see adult ADHD treatment. For the broader picture of how the main options differ, see stimulant vs nonstimulant ADHD medication.
Questions
Do ADHD medications make you lose weight?
Many adults lose a little weight early on. In Vyvanse's 4-week adult trial, average weight loss ranged from 2.8 to 4.3 pounds across dose groups, while the placebo group gained slightly. Adderall XR's adult trial reported weight loss in 10% of people on the drug vs none on placebo.
Can I take Vyvanse or Adderall to lose weight?
No ADHD medication is approved for weight loss. The Vyvanse label says it is not indicated or recommended for weight loss and that its safety and effectiveness for obesity have not been established. Using a stimulant beyond the prescription to suppress appetite is misuse.
Do nonstimulant ADHD medications affect appetite?
Yes, though the label figures are lower than for stimulants. Decreased appetite was reported by 16% of adults on Strattera and 10% on Qelbree, and both cause nausea more often than placebo.
How often should my weight be checked on ADHD medication?
The UK NICE guideline NG87 recommends measuring weight every 6 months in adults, with BMI monitoring if treatment has changed weight. Your prescriber will set a schedule that fits your situation.
Is ADHD medication safe if I have had an eating disorder?
That depends on the person and the medication, so tell the prescriber about it before treatment starts. Bupropion, sometimes used off-label for ADHD, is contraindicated in people with current or prior bulimia or anorexia nervosa because of seizure risk.
Sources
- DailyMed: Adderall XR (mixed amphetamine salts) extended-release capsules prescribing information and Medication Guide, Takeda (label effective April 30, 2026)
- DailyMed: Vyvanse (lisdexamfetamine dimesylate) prescribing information and Medication Guide, Takeda (label effective April 30, 2026)
- DailyMed: Concerta (methylphenidate hydrochloride) extended-release tablets prescribing information and Medication Guide, Janssen (label effective April 20, 2026)
- DailyMed: Strattera (atomoxetine) capsules prescribing information and Medication Guide, Eli Lilly (label effective June 30, 2026)
- DailyMed: Qelbree (viloxazine) extended-release capsules prescribing information and Medication Guide, Supernus (label effective October 5, 2026)
- DailyMed: Wellbutrin XL (bupropion hydrochloride) extended-release tablets prescribing information (label effective February 10, 2026)
- Chierrito de Oliveira et al., Journal of Attention Disorders 2019;23(2):111-120: Safety of treatments for ADHD in adults, pairwise and network meta-analyses
- NICE guideline NG87: Attention deficit hyperactivity disorder: diagnosis and management, Recommendations (section 1.8, monitoring)
- US Food and Drug Administration: FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions (May 11, 2023)
